Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Bolt Biotherapeutics Inc
BOLT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$6.65
0.06
0.91%
Ult. Agg.: Oct 26, 7:59 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Fusioni e acquisizioni:
Prana Therapies, Inc was acquired by Bolt Biotherapeutics (BOLT) on Friday, October 23, 2026
Bolt Biotherapeutics Financials
Bolt Biotherapeutics (BOLT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of $(7.60) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q3 EPS $(3.72) Beats $(5.53) Estimate, Sales $2.169M Beat $725.000K Estimate
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q2 EPS $(4.46) Beats $(6.27) Estimate, Sales $1.80M Beat $819.75K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of $(6.27) by 28.83 percent. This is a 60.18 percent increase over losses of $(11.20) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share
Benzinga Newsdesk
